Wire · operational-macro
Sentynl bets up to $475M in licensing deal for Mereo's rare lung disease asset
Sentynl has entered a licensing deal worth up to $475 million for Mereo BioPharma's rare lung disease asset, alvelestat, which is expected to start Phase 3 development for Alpha-1 Antitrypsin Deficiency Lung Disease (AATD-LD) in 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Investment in Mereo’s rare lung disease drug signals growing confidence in rare disease biotechs. You should watch licensing deals as they open routes to late-stage development assets you could partner with or compete against.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics
Biotechrare-diseaselicensing-dealdrug-developmentphase-3biotech